The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | Impact of comorbidities on patient selection for combination therapies in CLL
Catherine Coombs, MD, UCI Health, Orange, CA, discusses how comorbidities play a role in deciding which patients with chronic lymphocytic leukemia (CLL) should undergo combination treatment with BTK and BCL2 inhibitors. Dr Coombs believes most patients are candidates for combination therapies but emphasizes that patient discussions are key in the decision-making process. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
